ES2315358T3 - Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico. - Google Patents

Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico. Download PDF

Info

Publication number
ES2315358T3
ES2315358T3 ES02721337T ES02721337T ES2315358T3 ES 2315358 T3 ES2315358 T3 ES 2315358T3 ES 02721337 T ES02721337 T ES 02721337T ES 02721337 T ES02721337 T ES 02721337T ES 2315358 T3 ES2315358 T3 ES 2315358T3
Authority
ES
Spain
Prior art keywords
leptin
nicotinic acid
levels
ester
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02721337T
Other languages
English (en)
Spanish (es)
Inventor
Elaine University of Arizona JACOBSON
Myron K. University of Arizona JACOBSON
Hyuntae University of Arizona KIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
University of Arizona
Original Assignee
University of Kentucky Research Foundation
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2315358(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Kentucky Research Foundation, University of Arizona filed Critical University of Kentucky Research Foundation
Application granted granted Critical
Publication of ES2315358T3 publication Critical patent/ES2315358T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES02721337T 2001-03-08 2002-03-08 Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico. Expired - Lifetime ES2315358T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08
US274349P 2001-03-08

Publications (1)

Publication Number Publication Date
ES2315358T3 true ES2315358T3 (es) 2009-04-01

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02721337T Expired - Lifetime ES2315358T3 (es) 2001-03-08 2002-03-08 Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico.

Country Status (12)

Country Link
US (2) US6750234B2 (https=)
EP (1) EP1365762B1 (https=)
JP (1) JP5057353B2 (https=)
CN (1) CN1265792C (https=)
AT (1) ATE409037T1 (https=)
CA (1) CA2437844C (https=)
DE (1) DE60229041D1 (https=)
DK (1) DK1365762T3 (https=)
ES (1) ES2315358T3 (https=)
MX (1) MXPA03008096A (https=)
PT (1) PT1365762E (https=)
WO (1) WO2002072092A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002072092A1 (en) * 2001-03-08 2002-09-19 University Of Kentucky Method for increasing leptin levels using nicotinic acid compounds
JP5204947B2 (ja) * 2002-11-27 2013-06-05 ディーエムアイ バイオサイエンシズ インコーポレイテッド リン酸受容体化合物の使用、ならびにリン酸受容体化合物を含んでいる、薬学的組成物、スキンケア用の組成物、およびキット
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
WO2006044718A2 (en) 2004-10-14 2006-04-27 Flarion Technologies, Inc. Methods and apparatus for determining, communicating and using information which can be used for interference control purposes
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
CN103127111B (zh) * 2005-06-24 2016-02-10 代表亚利桑那大学的亚利桑那校董会 用于治疗头发生长病症比如女性型脱发的方法及可用于此的组合物
EP2462944A3 (en) 2005-08-29 2012-09-12 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8989084B2 (en) 2005-10-14 2015-03-24 Qualcomm Incorporated Methods and apparatus for broadcasting loading information corresponding to neighboring base stations
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US20070253449A1 (en) 2005-12-22 2007-11-01 Arnab Das Methods and apparatus related to determining, communicating, and/or using delay information
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
WO2008026349A1 (fr) * 2006-08-31 2008-03-06 Juridical Foundation Osaka Industrial Promotion Organization Agent thérapeutique destiné au traitement de l'effluvium télogène
PL2120917T3 (pl) * 2007-02-28 2014-09-30 Univ Kentucky Res Found Sposób na łagodzenie działań niepożądanych terapii kwasem retinowym i/lub ulepszanie skuteczności bez zakłócania skuteczności
JP2013516500A (ja) 2010-01-11 2013-05-13 ヒールオア・リミテッド 炎症性疾患および障害を治療するための方法
EP3446689B1 (en) * 2016-04-22 2025-01-08 JC (Wuxi) COMPANY, Inc. Isothiocyanate compound for use in the treatment of hyperbilirubinemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3570598D1 (en) * 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
JP2657583B2 (ja) * 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
EP0815230A2 (en) * 1995-03-20 1998-01-07 Ligand Pharmaceuticals, Inc. MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR
US6015821A (en) * 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
US20040102358A1 (en) * 1997-05-19 2004-05-27 Scivoletto Rosemarie Composition for treating skin conditions
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
DE69919403T2 (de) * 1998-12-01 2005-09-08 The University Of Kentucky Research Foundation Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
WO2002072092A1 (en) * 2001-03-08 2002-09-19 University Of Kentucky Method for increasing leptin levels using nicotinic acid compounds

Also Published As

Publication number Publication date
ATE409037T1 (de) 2008-10-15
EP1365762A4 (en) 2005-05-25
EP1365762A1 (en) 2003-12-03
CA2437844A1 (en) 2002-09-19
US20020128298A1 (en) 2002-09-12
US6750234B2 (en) 2004-06-15
CN1496260A (zh) 2004-05-12
MXPA03008096A (es) 2005-10-05
HK1065941A1 (en) 2005-03-11
WO2002072092A1 (en) 2002-09-19
DE60229041D1 (de) 2008-11-06
CA2437844C (en) 2007-05-15
US20040198776A1 (en) 2004-10-07
PT1365762E (pt) 2008-11-27
JP2004519488A (ja) 2004-07-02
JP5057353B2 (ja) 2012-10-24
DK1365762T3 (da) 2008-11-17
EP1365762B1 (en) 2008-09-24
CN1265792C (zh) 2006-07-26

Similar Documents

Publication Publication Date Title
ES2315358T3 (es) Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico.
ES2371671T3 (es) Uso de ácido fenilbutírico o sales del mismo para tratar el prurito.
US8846039B2 (en) Method for ameliorating pruritus
ES2245028T3 (es) Uso de lactoferrina en el tratamiento de trastornos inducidos por alergenos.
CA2688766C (en) Compositions and methods for treatment of multiple sclerosis
JP4307561B2 (ja) 創傷の治癒
AU2023233094B2 (en) Anti-inflammatory agents
US6558656B2 (en) Oral and topical compositions and methods related thereto in the treatment of acne
CA2142455A1 (en) Method for systemic treatment of catabolic conditions and systemic tissue injury
CA2280770C (en) Gene therapy for alleviating erectile dysfunction
JP2020515294A (ja) アブラナ科のタンパク質抽出物およびその使用
PEDEN et al. Anabolic effect of a new synthetic steroid on nitrogen metabolism after operation
AU2009202036A1 (en) Method for Ameliorating Pruritus
US9480675B2 (en) Method for increasing muscle growth by blocking sirtuin activity
JP2023136994A (ja) 爪幹細胞及び毛髪の成長を助長する外用剤
JPH0344313A (ja) 育毛剤
US20190248834A1 (en) Endomorphin-2, tetrapeptide derivatives thereof, and uses thereof
HK1065941B (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
JP2001261573A (ja) 腫瘍転移抑制剤
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis
JPWO1993015753A1 (ja) 気道系疾患治療剤